In vitro activity of lascufloxacin against Streptococcus pneumoniae with mutations in the quinolone resistance-determining regions (QRDRs) [PublishAheadOfPrint]

Lascufloxacin showed potent activity against Streptococcus pneumoniae with GyrA or ParC mutation (first-step mutants). The frequency of selecting resistant strains tended to be lower for lascufloxacin than levofloxacin and garenoxacin after drug exposure in first-step mutants, but was similar in the comparison between lascufloxacin and moxifloxacin. The increase in MIC was smaller for lascufloxacin than for levofloxacin, garenoxacin, and moxifloxacin when clinical strains with only ParC mutation were exposed to the corresponding drug.

http://ift.tt/2o2lu1r